Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1524228

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1524228

Loratadine Market - By Dosage Form (Tablets, Capsules, Syrups), Route of Administration (Oral, Topical), Type (Branded, Generis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032)

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 5350
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

Global Loratadine Market will grow at 2.8% CAGR from 2024 to 2032, propelled by advancements in pharmaceutical formulations and increased consumer awareness. Innovations in drug delivery and enhanced formulations are improving the efficacy and patient compliance of loratadine, making it a preferred choice for allergy relief. Also, the growing consumer education about allergy management and the benefits of non-drowsy antihistamines are boosting the product demand. These factors, coupled with effective marketing strategies, and the growing importance of loratadine in the evolving pharmaceutical landscape will favor the industry growth.

The loratadine market is fragmented into dosage form, route of administration, type, distribution channel, and region.

By dosage form, the industry size from the capsules segment will experience a substantial surge between 2024 and 2032, fueled by rising consumer preference for ease of ingestion and dosage accuracy. Capsules offer convenient packaging and effective delivery of antihistamine while catering to a broad spectrum of users seeking allergy relief. Attributes like portability and shelf stability to appeal to both healthcare providers and consumers will also boost the product demand.

Based on distribution channel, the loratadine industry from the hospital pharmacy segment will capture sizable gains through 2032, driven by strong role in dispensing medications for acute and chronic conditions like allergies. The large patient base and extensive use of antihistamines in treatment protocols is contributing to high product demand in hospitals. With increasing healthcare facilities and patient admissions globally, hospital pharmacies have grown crucial for driving the majority of loratadine sales while ensuring widespread accessibility and distribution.

Asia Pacific loratadine industry share will expand at a noteworthy CAGR from 2024 to 2032, owing to increasing incidences of allergies and respiratory conditions. Rapid urbanization, rising healthcare expenditure, and expanding access to healthcare services are contributing to higher product demand. Moreover, regulatory approvals and growing investments in pharmaceuticals are bolstering the market growth in the region.

Product Code: 9141

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of allergic conditions
      • 3.2.1.2 Availability of over-the-counter (OTC) formulations
      • 3.2.1.3 Increasing R&D in loratadine combinations
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Risk of potential side-effects
      • 3.2.2.2 Competition from other antihistamines
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tablets
  • 5.3 Capsules
  • 5.4 Syrups
  • 5.5 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Topical

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Bayer AG
  • 10.2 Cadila Pharmaceuticals Limited
  • 10.3 Cipla Ltd.
  • 10.4 Lannett Company, Inc.
  • 10.5 Merck KGaA
  • 10.6 Morepen Laboratories Ltd
  • 10.7 Perrigo Company plc
  • 10.8 Pfizer Inc.
  • 10.9 Sun Pharmaceutical Industries Limited
  • 10.10 Viatris Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!